{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:15:42Z","timestamp":1784754942311,"version":"3.55.0"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glofitamab offers a promising option for the treatment of diffuse large B-cell lymphoma. It is crucial to gather comprehensive safety information of glofitamab through large-scale post market monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study conducted a comprehensive analysis of glofitamab-related adverse events (AEs) based on FDA Adverse Event Reporting System database. Four disproportionality analysis methods were employed to mining the significant signals. The clinical characteristics of all AE and cytokine release syndrome reports were analyzed. Sensitivity analyses were performed to exam the potential bias. The differences in AE signals among different subgroups were investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 641 reports and 1,542 AEs with glofitamab were identified. Cytokine release syndrome was the most significant signal. Notably, American and European reporters demonstrated higher cytokine release syndrome reporting frequency. Cytokine release syndrome was often reported by professionals and occurred within 30 days, especially with glofitamab at a dose of 2.5\u2009mg. Hypogammaglobulinaemia was discovered as a new significant AE signal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The findings suggest potential reporting differences in glofitamab-related AEs across different continents. Educating consumers on how to recognize the early symptoms of cytokine release syndrome is essential to improve safety. Close monitoring of cytokine release syndrome is recommended within 30 days of administration of glofitamab, especially at a dose of 2.5\u2009mg. Furthermore, it is essential to stay vigilant about the emergence of the newly identified AE. These findings contribute to a broader understanding of the AE profiles of glofitamab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0336151","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:27:22Z","timestamp":1762280842000},"page":"e0336151","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploration of adverse event profiles for glofitamab: A disproportionality analysis using the FDA adverse event reporting system"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8598-5643","authenticated-orcid":true,"given":"Meng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8454-749X","authenticated-orcid":true,"given":"Cheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanyong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"issue":"9","key":"pone.0336151.ref001","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.24086","article-title":"Non-hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011","volume":"90","author":"M Al-Hamadani","year":"2015","journal-title":"Am J Hematol"},{"issue":"5","key":"pone.0336151.ref002","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/j.seminhematol.2023.11.004","article-title":"Epidemiology and etiology of diffuse large B-cell lymphoma","volume":"60","author":"SS Wang","year":"2023","journal-title":"Semin Hematol"},{"issue":"9","key":"pone.0336151.ref003","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"LH Sehn","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"pone.0336151.ref004","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"R Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0336151.ref005","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"B Coiffier","year":"2010","journal-title":"Blood"},{"issue":"2","key":"pone.0336151.ref006","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ijc.35156","article-title":"The future of immunotherapy for diffuse large B\u2010cell lymphoma","volume":"156","author":"J Duell","year":"2024","journal-title":"Intl Journal of Cancer"},{"issue":"10","key":"pone.0336151.ref007","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40265-023-01894-5","article-title":"Glofitamab: first approval","volume":"83","author":"M Shirley","year":"2023","journal-title":"Drugs"},{"issue":"4","key":"pone.0336151.ref008","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood.2024024168","article-title":"Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma","volume":"144","author":"JK Godfrey","year":"2024","journal-title":"Blood"},{"issue":"24","key":"pone.0336151.ref009","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"MJ Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"pone.0336151.ref010","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/bloodadvances.2024014903","article-title":"Safety and efficacy of glofitamab for relapsed\/refractory large B-cell lymphoma in a multinational real-world study","volume":"9","author":"E Shumilov","year":"2025","journal-title":"Blood Adv"},{"issue":"18","key":"pone.0336151.ref011","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-Cell lymphoma: a phase I trial","volume":"39","author":"M Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0336151.ref012","first-page":"1269","article-title":"Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma","volume":"109","author":"Y-Q Song","year":"2024","journal-title":"Haematologica"},{"key":"pone.0336151.ref013","doi-asserted-by":"crossref","first-page":"1566035","DOI":"10.3389\/fimmu.2025.1566035","article-title":"Successful treatment of primary refractory DLBCL\/HGBL - MYC\/BCL2 transformed from FL using glofitamab: a case report","volume":"16","author":"M-Q Chu","year":"2025","journal-title":"Front Immunol"},{"key":"pone.0336151.ref014","first-page":"79","article-title":"A case report of sustained cytokine release syndrome due to glofitamab and literature review","volume":"17","author":"J Yang","year":"2025","journal-title":"Clin Pharmacol"},{"issue":"17","key":"pone.0336151.ref015","doi-asserted-by":"crossref","first-page":"9736","DOI":"10.3390\/ijms25179736","article-title":"Safety and efficacy of bispecific antibodies in adults with large B-cell lymphomas: a systematic review of clinical trial data","volume":"25","author":"E Bayly-McCredie","year":"2024","journal-title":"Int J Mol Sci"},{"key":"pone.0336151.ref016","doi-asserted-by":"crossref","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","volume":"59","author":"C Zhou","year":"2023","journal-title":"eClinicalMed"},{"issue":"1","key":"pone.0336151.ref017","doi-asserted-by":"crossref","first-page":"11388","DOI":"10.1038\/s41598-024-62356-w","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib","volume":"14","author":"Y Qi","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0336151.ref018","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1161","article-title":"Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post-marketing safety","volume":"12","author":"C Jiang","year":"2024","journal-title":"Pharmacol Res Perspect"},{"key":"pone.0336151.ref019","doi-asserted-by":"crossref","first-page":"20420986241258049","DOI":"10.1177\/20420986241258049","article-title":"A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime","volume":"15","author":"C Jiang","year":"2024","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"pone.0336151.ref020","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s10194-024-01858-4","article-title":"Post-marketing safety concerns with rimegepant based on a pharmacovigilance study","volume":"25","author":"J-L Hu","year":"2024","journal-title":"J Headache Pain"},{"issue":"5","key":"pone.0336151.ref021","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/14740338.2024.2371382","article-title":"Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database","volume":"24","author":"X Wan","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"pone.0336151.ref022","doi-asserted-by":"crossref","DOI":"10.1177\/20420986231154075","article-title":"Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database","volume":"14","author":"AF Altebainawi","year":"2023","journal-title":"Ther Adv Drug Saf"},{"issue":"3","key":"pone.0336151.ref023","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000505376","article-title":"Fractures due to aromatase inhibitor therapy for breast cancer: a real-world analysis of FAERS data in the past 15 years","volume":"43","author":"Y Song","year":"2020","journal-title":"Oncol Res Treat"},{"issue":"1","key":"pone.0336151.ref024","doi-asserted-by":"crossref","first-page":"20601","DOI":"10.1038\/s41598-022-23726-4","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib","volume":"12","author":"M Guo","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0336151.ref025","doi-asserted-by":"crossref","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for osimertinib","volume":"12","author":"Y Yin","year":"2022","journal-title":"Sci Rep"},{"key":"pone.0336151.ref026","doi-asserted-by":"crossref","first-page":"377","DOI":"10.18433\/jpps33020","article-title":"Post-marketing safety of vemurafenib: a real-world pharmacovigilance study of the FDA adverse event reporting system","volume":"25","author":"Y Liu","year":"2022","journal-title":"J Pharm Pharm Sci"},{"issue":"2","key":"pone.0336151.ref027","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/bcp.15277","article-title":"Pharmacovigilance in China: evolution and future challenges","volume":"89","author":"H Song","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"10466","key":"pone.0336151.ref028","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"JS Abramson","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"pone.0336151.ref029","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.3390\/cancers14102516","article-title":"Glofitamab treatment in relapsed or refractory DLBCL after CAR T-cell therapy","volume":"14","author":"V Rentsch","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"pone.0336151.ref030","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s43018-025-00941-2","article-title":"Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study","volume":"6","author":"G Cartron","year":"2025","journal-title":"Nat Cancer"},{"key":"pone.0336151.ref031","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood-2024-199330","article-title":"Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for relapsed or refractory large B-cell lymphoma: a multi-center, retrospective cohort study","volume":"144","author":"TR Brooks","year":"2024","journal-title":"Blood"},{"key":"pone.0336151.ref032","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70096_671","article-title":"Glofitamab for the treatment of relapsed\/refractory diffuse large B cell lymphoma, a real\u2010world evidence study from the cubic consortium","volume":"43","author":"G Shouse","year":"2025","journal-title":"Hematol Oncol"},{"issue":"4","key":"pone.0336151.ref033","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/hon.3174","article-title":"Glofitamab in relapsed\/refractory diffuse large B-cell lymphoma: real-world data","volume":"41","author":"E Birtas Atesoglu","year":"2023","journal-title":"Hematol Oncol"},{"issue":"10","key":"pone.0336151.ref034","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.6004\/jnccn.2016.0136","article-title":"High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex","volume":"14","author":"Z Zhou","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"14","key":"pone.0336151.ref035","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/ajhp\/zxae050","article-title":"Pharmacist perspectives on emerging T cell-engaging bispecific therapies in cancer therapeutics","volume":"81","author":"DC Moore","year":"2024","journal-title":"Am J Health Syst Pharm"},{"key":"pone.0336151.ref036","doi-asserted-by":"crossref","first-page":"1190379","DOI":"10.3389\/fimmu.2023.1190379","article-title":"Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures","volume":"14","author":"D Shah","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0336151.ref037","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"MS Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"pone.0336151.ref038","doi-asserted-by":"crossref","first-page":"101316","DOI":"10.1016\/j.blre.2025.101316","article-title":"Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: pathophysiology, clinical implications, management options, and future directions","author":"A Wonnaparhown","year":"2025","journal-title":"Blood Rev"},{"issue":"6","key":"pone.0336151.ref039","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"MH Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"pone.0336151.ref040","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1086\/596756","article-title":"HIV-associated opportunistic infections--going, going, but not gone: the continued need for prevention and treatment guidelines","volume":"48","author":"JT Brooks","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0336151.ref041","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bjh.19668","article-title":"Mitigating infection risks: The promise and challenge of bispecific antibodies in haematological malignancies","volume":"205","author":"H Rafei","year":"2024","journal-title":"Br J Haematol"},{"key":"pone.0336151.ref042","doi-asserted-by":"crossref","first-page":"100810","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap","volume":"49","author":"AP Longhitano","year":"2021","journal-title":"Blood Rev"},{"issue":"4","key":"pone.0336151.ref043","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.chmed.2024.01.002","article-title":"Mechanisms of shufeng jiedu capsule in treating bacterial pneumonia based on network pharmacology and experimental verification","volume":"16","author":"Y Xu","year":"2024","journal-title":"Chinese Herbal Medicines"},{"issue":"3","key":"pone.0336151.ref044","first-page":"358","article-title":"Ethnopharmacology, chemical composition and functions of Cymbopogon citratus","volume":"16","author":"X Du","year":"2023","journal-title":"Chin Herb Med"},{"issue":"4","key":"pone.0336151.ref045","first-page":"548","article-title":"Mechanism of action of protopanaxadiol ginsenosides on hepatocellular carcinoma and network pharmacological analysis","volume":"16","author":"Y Zhou","year":"2024","journal-title":"Chin Herb Med"},{"issue":"3","key":"pone.0336151.ref046","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.chmed.2023.09.007","article-title":"Bioactive components, pharmacological properties and underlying mechanism of Ganoderma lucidum spore oil: a review","volume":"16","author":"J Liu","year":"2024","journal-title":"Chin Herbal Med"},{"issue":"4","key":"pone.0336151.ref047","first-page":"638","article-title":"Network pharmacology, molecular docking, and untargeted metabolomics reveal molecular mechanisms of multi-targets effects of Qingfei Tongluo Plaster improving respiratory syncytial virus pneumonia","volume":"16","author":"M Yang","year":"2024","journal-title":"Chin Herb Med"},{"issue":"3","key":"pone.0336151.ref048","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a Phase I\/II study","volume":"43","author":"TJ Phillips","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0336151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:27:30Z","timestamp":1762280850000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0336151"}},"subtitle":[],"editor":[{"given":"Abhinava Kumar","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":48,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0336151","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]}}}